SLU-PP-332: The Exercise Mimetic Compound Rewriting Muscle Biology

SLU-PP-332 is a small molecule agonist of the estrogen-related receptor (ERR) family — specifically ERRα, ERRβ, and ERRγ — developed by researchers at Washington University in St. Louis (hence "SLU") under the direction of Dr. Thomas Burris. While technically not a peptide in the strict biochemical definition (it is a small molecule rather than an amino acid chain), SLU-PP-332 is widely discussed in peptide research communities because it targets the same molecular pathways that growth hormone-releasing peptides and metabolic peptides modulate, and it is frequently sourced from peptide research suppliers.

The "exercise mimetic" designation reflects SLU-PP-332's ability to activate gene expression programs that are normally only triggered by physical exercise. During exercise, particularly endurance training, muscles undergo a coordinated molecular response involving hundreds of genes that enhance oxidative metabolism, mitochondrial biogenesis, fatty acid oxidation, and fatigue resistance. ERR proteins are master transcription factors that orchestrate much of this response. SLU-PP-332 activates these ERR proteins directly, bypassing the need for the mechanical and metabolic stress of exercise to trigger these adaptations.

A landmark 2023 study published in Nature by Xia et al. demonstrated that SLU-PP-332 treatment produced remarkable exercise-like adaptations in mice — including increased oxidative muscle fiber content, enhanced endurance capacity, and improved metabolic profiles — without any change in physical activity. These findings generated significant scientific and media attention, positioning SLU-PP-332 as a leading candidate in the "exercise in a pill" research space. For context on how research compounds interact with metabolic pathways, see our peptide fundamentals guide.

Understanding SLU-PP-332 requires understanding the ERR family of nuclear receptors and their central role in exercise physiology:

Estrogen-related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors — transcription factors named for their structural similarity to estrogen receptors but which do not bind estrogen. Despite the confusing nomenclature, ERRs function independently of estrogen signaling. They are constitutively active transcription factors that regulate genes involved in energy metabolism, mitochondrial function, and muscle fiber specification.

ERRα: Expressed in virtually all tissues, ERRα is the primary metabolic regulator among the ERR family. It controls expression of genes involved in fatty acid oxidation (CPT1B, ACADM, ACADL), the tricarboxylic acid cycle (IDH3A, ACO2), oxidative phosphorylation (NDUFS1, SDHA, COX5A), and mitochondrial biogenesis (TFAM, NRF1). Exercise increases ERRα expression and activity, explaining many of exercise's metabolic benefits.

ERRβ: Less studied than ERRα, ERRβ plays roles in stem cell maintenance and early development but also contributes to metabolic gene regulation in skeletal muscle. ERRβ knockout mice show impaired oxidative capacity, suggesting a supportive role in exercise adaptation.

ERRγ: Highly expressed in oxidative tissues including the heart, kidneys, and slow-twitch (Type I) muscle fibers. ERRγ is a key determinant of muscle fiber type — its expression levels correlate directly with oxidative fiber content. Transgenic mice overexpressing ERRγ in skeletal muscle develop "marathon mouse" phenotypes with dramatically increased endurance capacity, enhanced fat oxidation, and resistance to diet-induced obesity.

SLU-PP-332 is a pan-ERR agonist, activating all three family members simultaneously. This broad activation recapitulates the full transcriptional response to exercise rather than targeting only one component. The compound binds to the ligand-binding domain of ERR proteins, stabilizing them in an active conformation that enhances transcription of target genes. For more on how molecular interventions can modulate metabolic pathways, explore our muscle growth peptide guide.

The 2023 study by Xia et al. in Nature provided the most compelling evidence for SLU-PP-332's exercise-mimetic properties. The key findings deserve detailed examination:

Muscle Fiber Type Conversion: Mice treated with SLU-PP-332 (50 mg/kg intraperitoneally, twice daily for 28 days) showed a significant shift in muscle fiber composition from glycolytic (Type IIb/IIx) fibers toward oxidative (Type I and Type IIa) fibers. In the soleus and gastrocnemius muscles, oxidative fiber content increased by 40-60% compared to vehicle-treated controls. This fiber type shift is identical to what occurs with chronic endurance training — normally requiring weeks to months of consistent aerobic exercise.

Enhanced Endurance Performance: Treadmill testing revealed that SLU-PP-332-treated mice ran approximately 50% longer and 45% farther than controls before exhaustion. This performance enhancement occurred without any change in daily activity levels — the mice were sedentary, yet performed as if they had been endurance-trained. Running economy (distance per unit energy expenditure) also improved, suggesting genuine metabolic efficiency gains rather than simply increased pain tolerance.

Metabolic Improvements: Treated mice showed increased whole-body fatty acid oxidation, reduced respiratory exchange ratio (indicating greater fat utilization), and improved glucose tolerance. Skeletal muscle gene expression profiling revealed upregulation of over 500 genes involved in oxidative metabolism, mitochondrial biogenesis, and fatty acid transport — a transcriptional signature nearly identical to that produced by endurance exercise.

Resistance to Muscle Wasting: In a high-fat diet model, SLU-PP-332 treatment partially prevented the decline in muscle quality and oxidative capacity typically caused by obesity. Treated mice on high-fat diets maintained 73% of their baseline treadmill performance, versus 41% in untreated controls — suggesting protective effects against obesity-induced muscle dysfunction.

Body Composition Effects: SLU-PP-332-treated mice on high-fat diets gained 10% less body weight than controls, with the difference attributable to reduced fat mass rather than lean mass changes. The modest magnitude of the weight effect suggests SLU-PP-332's primary benefits are metabolic efficiency and muscle quality rather than direct fat loss.

SLU-PP-332 is not the first compound investigated as an exercise mimetic. Understanding how it compares to predecessors provides important research context:

SLU-PP-332 vs. GW501516 (Cardarine): GW501516 is a PPARδ agonist that was one of the earliest compounds described as an "exercise mimetic." It enhances fatty acid oxidation and increases endurance capacity through PPARδ-mediated gene expression. However, GW501516 development was abandoned due to carcinogenicity concerns in preclinical studies — specifically, accelerated tumor growth in multiple organ systems at doses used in long-term animal studies. SLU-PP-332 targets a different pathway (ERR vs. PPAR) and has not shown carcinogenic signals in published studies, though long-term safety data is limited to current preclinical timeframes.

SLU-PP-332 vs. AICAR: AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) activates AMP-activated protein kinase (AMPK), the cellular energy sensor that triggers exercise-like metabolic adaptations. While AICAR increases endurance in animal models, it requires intravenous administration, has poor oral bioavailability, and produces relatively modest effects compared to SLU-PP-332. Additionally, AMPK activation stimulates both catabolic and anabolic pathways in ways that can be counterproductive — including activation of autophagy that may be excessive in some contexts.

SLU-PP-332 vs. Irisin/FNDC5: Irisin is a myokine (muscle-secreted hormone) released during exercise that promotes browning of white adipose tissue. While irisin reproduces one specific effect of exercise (thermogenic fat conversion), SLU-PP-332's pan-ERR activation produces a much broader exercise-mimetic response encompassing muscle fiber type conversion, mitochondrial biogenesis, and global metabolic reprogramming.

SLU-PP-332's advantage lies in targeting upstream master regulators (ERRs) rather than individual downstream pathways. This produces a more comprehensive exercise-like response, though it also means the effects are broad and potentially more difficult to control precisely. Explore our research compound catalog for verified exercise-related research compounds.

The ability to pharmacologically activate exercise pathways has profound implications for populations unable to exercise conventionally:

Muscle Wasting Diseases: Conditions like muscular dystrophy, sarcopenia (age-related muscle loss), cancer cachexia, and prolonged bed rest involve progressive loss of oxidative muscle fibers and mitochondrial function — exactly the pathways SLU-PP-332 activates. If exercise-mimetic compounds can maintain or restore oxidative muscle capacity in patients unable to exercise, the therapeutic impact would be substantial. Sarcopenia alone affects 10-16% of adults over 60, with annual healthcare costs exceeding $40 billion in the United States.

Metabolic Disease: Type 2 diabetes, obesity, and metabolic syndrome all involve impaired oxidative metabolism and mitochondrial dysfunction in skeletal muscle. Exercise is the most effective intervention for these conditions, but adherence rates are notoriously low (only 20-30% of patients maintain prescribed exercise programs). SLU-PP-332 could potentially provide metabolic benefits to patients who cannot achieve sufficient exercise due to physical limitations, mobility impairments, or severe obesity.

Heart Failure: ERRα and ERRγ are critical regulators of cardiac metabolism. Heart failure involves a metabolic shift from fatty acid oxidation to inefficient glucose utilization in cardiomyocytes. ERR agonism could theoretically restore cardiac metabolic efficiency, improving contractile function and exercise tolerance in heart failure patients.

Spinal Cord Injury and Immobilization: Patients with spinal cord injuries cannot voluntarily activate skeletal muscles below the injury level, leading to rapid muscle atrophy and metabolic derangement. An exercise mimetic that activates muscle metabolic programs without requiring neural-driven contraction could preserve muscle quality and systemic metabolic health in these populations.

Spaceflight Physiology: Microgravity causes rapid muscle atrophy and metabolic dysfunction in astronauts, despite current exercise countermeasures. NASA has expressed interest in pharmacological adjuncts to exercise for long-duration spaceflight missions. For more on metabolic research compounds, see our article on SS-31 peptide and mitochondrial function.

SLU-PP-332 remains in the early stages of research, and several important limitations temper the excitement surrounding its exercise-mimetic properties:

Preclinical Data Only: All published data on SLU-PP-332 comes from mouse and cell culture studies. No human clinical trials have been conducted or, as of early 2026, publicly registered. The translation from mouse exercise physiology to human physiology is not guaranteed — while the ERR pathway is conserved between species, differences in muscle fiber distribution, metabolic rate, and drug metabolism could significantly alter the compound's effects in humans.

Administration Route Challenges: The published mouse studies used intraperitoneal injection at 50 mg/kg twice daily — a relatively high dose and an impractical route for human use. Oral bioavailability data for SLU-PP-332 has not been published, and developing an orally available formulation at clinically relevant doses remains a significant pharmacological challenge.

Limited Safety Data: While 28-day preclinical studies showed no obvious toxicity, the long-term safety profile of ERR agonism is unknown. ERR proteins regulate gene expression in multiple tissues beyond skeletal muscle, including the heart, liver, kidneys, and brain. Chronic pan-ERR activation could have unintended effects in these tissues. Comprehensive toxicology studies are needed before human testing.

Not a Complete Exercise Replacement: Even if SLU-PP-332 perfectly replicates the metabolic and muscular adaptations to exercise, it cannot reproduce exercise's other benefits — cardiovascular conditioning, bone loading (preventing osteoporosis), neuroplasticity, psychological well-being, and social engagement. Any clinical application would likely position exercise mimetics as adjuncts to, rather than replacements for, physical activity.

Intellectual Property and Development Path: SLU-PP-332's development pathway from academic research to clinical application remains unclear. No pharmaceutical company has publicly announced licensing or development plans for SLU-PP-332 specifically, though multiple companies are pursuing ERR-targeted approaches. The timeline to potential clinical availability is likely years, not months.

SLU-PP-332 is part of a growing field of exercise mimetic research that reflects increasing scientific interest in pharmacologically activating exercise pathways:

Molecular Targets Under Investigation: Beyond ERR agonism, researchers are pursuing AMPK activators, PGC-1α pathway modulators, myokine analogs (irisin, meteorin-like, BAIBA), mitochondrial-targeted compounds, and sirtuin activators. Each approach mimics a different facet of exercise adaptation, and the eventual clinical strategy may involve combination regimens targeting multiple pathways simultaneously — analogous to how actual exercise activates hundreds of molecular programs simultaneously.

NAD+ Precursors: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors that support mitochondrial function and sirtuin activity — key components of the exercise response. While not exercise mimetics in the strict sense, NAD+ supplementation produces some overlapping metabolic benefits. Learn more in our NAD+ peptide research guide.

Regulatory and Ethical Considerations: Exercise mimetics raise important questions about athletic doping, equitable access, and the medicalization of sedentary lifestyles. WADA (World Anti-Doping Agency) has already banned GW501516 and AICAR, and would likely move quickly to ban any clinically effective exercise mimetic. The ethical debate — whether providing metabolic benefits to those unable to exercise is different from enhancing already-healthy athletes — mirrors existing discussions around peptide therapy regulation.

Integration with Peptide Research: SLU-PP-332's mechanisms overlap with several established peptide research areas. Growth hormone-releasing peptides and IGF-1-modulating compounds influence many of the same muscle growth and metabolic pathways. Mitochondria-targeted peptides like SS-31 address the mitochondrial biogenesis component. The convergence of small molecule exercise mimetics with peptide-based metabolic modulators may define the next generation of metabolic research compounds. For ongoing developments in metabolic research, visit our peptide therapy guide.

For researchers interested in SLU-PP-332, several practical factors warrant attention:

Sourcing: SLU-PP-332 is available from specialized research chemical suppliers, though availability is more limited than established peptides. When sourcing, verify that the supplier provides HPLC purity data (≥95% for small molecules), mass spectrometry identity confirmation, and batch-specific certificates of analysis. The compound's chemical structure (molecular formula C26H23FN2O3S, MW 462.53) should be confirmed by the supplier's analytical data.

Solubility and Preparation: SLU-PP-332 is typically supplied as a powder requiring dissolution in DMSO for in vitro work or formulation in suitable vehicles for in vivo studies. The published mouse studies used intraperitoneal injection in a vehicle of 10% DMSO/90% corn oil. Researchers should verify solubility and stability in their specific experimental conditions.

Dosing Translation: The 50 mg/kg dose used in mouse studies does not translate directly to human-equivalent doses. Using standard allometric scaling (FDA guidance for estimating human equivalent doses), the mouse dose would correspond to approximately 4 mg/kg in humans — roughly 280-320 mg for a 70-80 kg adult. However, this calculation is preliminary, and actual human dosing would require formal pharmacokinetic studies.

Experimental Controls: Exercise mimetic research requires careful experimental design. Positive controls should include an exercise group (treadmill running, swimming) to benchmark SLU-PP-332's effects against actual exercise. Pathway-specific readouts — ERR target gene expression (CPT1B, ACADM, TFAM, COX5A), fiber type immunohistochemistry, mitochondrial enzyme activity assays — should be included alongside functional outcomes. All research protocols should include appropriate institutional oversight and follow applicable regulatory guidelines. Visit our about page for information on research compound quality standards.